Skip to Content

AbbVie Inc ABBV

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat




Annual Pipeline Review of Leading Big Pharma and Biotech Supports Moats

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Most Big Pharma and Big Biotech stocks in our coverage support wide economic moats as a result of their ability to generate new drugs to replace mature ones losing patent protection. Innovation is the central building block for the strong economic moats in the drug and biotechnology industry, supporting drug pricing power and launch trajectories. However, following patent expirations, drug sales fall significantly, making the continuous cycle of new drugs essential to the moats in the industry. In looking at the leading large-cap U.S. and European drug and biotech industries, we expect steady innovation to drive 5% annual sales growth over the next five years, similar to consensus expectations. Overlaying our growth analysis with valuation, we see underappreciated areas: Roche's Tecentriq in several cancer niches; Bristol-Myers Squibb's steady position in immuno-oncology and massive pipeline and cash flow support from Celgene; Merck's oncology portfolio and vaccine and animal health cash flows; and Pfizer's new immunology drugs and strong vaccine positioning.

Read Full Analysis

Company Profile

Business Description

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.

1 North Waukegan Road
North Chicago, IL, 60064-6400
T +1 847 932-7900
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type High Yield
Employees 30,000